Form 4: Pfizer Director Susan Desmond-Hellmann Acquires Stock Units

Pfizer Inc. director Susan Desmond-Hellmann was granted 7,686.539 phantom stock units as part of deferred director compensation.

Summary

• Director Susan Desmond-Hellmann acquired 7,686.539 phantom stock units on April 23, 2026.
• The units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
• Each unit represents one phantom share of common stock valued at $26.67 per unit.
• The total beneficial ownership following this transaction is 45,635.605 units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or strategy.

Positives

• Director alignment with company performance through equity-based compensation.

Negatives

• None identified.

Risks

• Value of phantom stock units is subject to the future market performance of Pfizer common stock.

Future Outlook

The units are settled in cash or common stock at the director's election following their retirement from the Board of Directors.

Industry Context

StockSavvy.ai notes that director compensation via deferred stock units is a standard corporate governance practice in the pharmaceutical industry to ensure long-term alignment between board members and shareholders.

Comparison to Industry Standards

• The use of deferred compensation plans for non-employee directors is consistent with practices at major pharmaceutical peers like Merck, Bristol Myers Squibb, and Eli Lilly.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation disclosure.

Next Steps

• Settlement of units in cash or common stock upon the director's retirement from the Board.

Key Dates

Keywords

Pfizer, PFE, Form 4, Insider Trading, Director Compensation, Phantom Stock